» Articles » PMID: 22404856

Relevance of Animal Models to Human Tardive Dyskinesia

Overview
Publisher Biomed Central
Date 2012 Mar 13
PMID 22404856
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Tardive dyskinesia remains an elusive and significant clinical entity that can possibly be understood via experimentation with animal models. We conducted a literature review on tardive dyskinesia modeling. Subchronic antipsychotic drug exposure is a standard approach to model tardive dyskinesia in rodents. Vacuous chewing movements constitute the most common pattern of expression of purposeless oral movements and represent an impermanent response, with individual and strain susceptibility differences. Transgenic mice are also used to address the contribution of adaptive and maladaptive signals induced during antipsychotic drug exposure. An emphasis on non-human primate modeling is proposed, and past experimental observations reviewed in various monkey species. Rodent and primate models are complementary, but the non-human primate model appears more convincingly similar to the human condition and better suited to address therapeutic issues against tardive dyskinesia.

Citing Articles

Cannabigerol Mitigates Haloperidol-Induced Vacuous Chewing Movements in Mice.

Ponciano R, Hallak J, Crippa J, Guimaraes F, Bel E Neurotox Res. 2024; 43(1):2.

PMID: 39699828 DOI: 10.1007/s12640-024-00724-0.


Molecular and Behavioral Neuroprotective Effects of Clavulanic Acid and Crocin in Haloperidol-Induced Tardive Dyskinesia in Rats.

Shoae-Hagh P, Razavi B, Sadeghnia H, Mehri S, Karimi G, Hosseinzadeh H Mol Neurobiol. 2024; 62(4):5156-5182.

PMID: 39520654 DOI: 10.1007/s12035-024-04566-x.


Animal models of Parkinson's disease: bridging the gap between disease hallmarks and research questions.

Dovonou A, Bolduc C, Soto Linan V, Gora C, Peralta Iii M, Levesque M Transl Neurodegener. 2023; 12(1):36.

PMID: 37468944 PMC: 10354932. DOI: 10.1186/s40035-023-00368-8.


Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies.

Tsermpini E, Redensek S, Dolzan V Front Pharmacol. 2022; 12:834129.

PMID: 35140610 PMC: 8819690. DOI: 10.3389/fphar.2021.834129.


Management of Tardive Syndrome: Medications and Surgical Treatments.

Factor S Neurotherapeutics. 2020; 17(4):1694-1712.

PMID: 32720245 PMC: 7851276. DOI: 10.1007/s13311-020-00898-3.


References
1.
Pedata F, Sorbi S, Pepeu G . Choline high-affinity uptake and metabolism and choline acetyltransferase activity in the striatum of rats chronically treated with neuroleptics. J Neurochem. 1980; 35(3):606-11. DOI: 10.1111/j.1471-4159.1980.tb03698.x. View

2.
Novak G, Gallo A, Zai C, Meltzer H, Lieberman J, Potkin S . Association of the orphan nuclear receptor NR4A1 with tardive dyskinesia. Psychiatr Genet. 2009; 20(1):39-43. DOI: 10.1097/YPG.0b013e3283351221. View

3.
Kostrzewa R, Huang N, Kostrzewa J, Nowak P, Brus R . Modeling tardive dyskinesia: predictive 5-HT2C receptor antagonist treatment. Neurotox Res. 2007; 11(1):41-50. DOI: 10.1007/BF03033481. View

4.
Samaha A, Reckless G, Seeman P, Diwan M, Nobrega J, Kapur S . Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. Biol Psychiatry. 2008; 64(2):145-52. DOI: 10.1016/j.biopsych.2008.01.010. View

5.
Woods S, Morgenstern H, Saksa J, Walsh B, Sullivan M, Money R . Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry. 2010; 71(4):463-74. PMC: 3109728. DOI: 10.4088/JCP.07m03890yel. View